Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Duloxetine Stories

2014-04-03 08:28:55

Product has fast track designation by FDA RALEIGH, N.C., April 3, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The Phase 3 trial is a multicenter, randomized, double blind, placebo controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment...

2014-03-25 00:23:16

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rt6msb/investigation) has announced the addition of the "Investigation Report on China Duloxetine Market" [http://www.researchandmarkets.com/research/rt6msb/investigation ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Depression is a common mood disorder that belongs to high-incidence mental...

2014-03-04 23:02:22

The Osteoarthritis Research Society International (OARSI) releases new evidence-based guidelines for the non-surgical treatment of osteoarthritis of the knee that, for the first time, are targeted to differing patient characteristics. Mount Laurel, NJ (PRWEB) March 04, 2014 The Osteoarthritis Research Society International (OARSI) releases new evidence-based guidelines for the non-surgical treatment of osteoarthritis of the knee that, for the first time, are targeted to differing patient...

2014-02-14 16:25:45

DUBLIN, February 14, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pdhgfs/pain_management) has announced the addition of the "Pain Management Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2018" [http://www.researchandmarkets.com/research/pdhgfs/pain_management ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global pain management...

2013-12-12 12:27:32

MUMBAI, India and BALTIMORE, December 12, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg strengths. The Company received final approval to market its Duloxetine HCl DR Capsules USP, 20 mg, 30 mg, 40 mg and 60 mg strengths from the United States Food and Drugs Administration (FDA) yesterday....

2013-12-02 08:30:12

Phase 3 to begin first quarter 2014; Fast track designation confirmed for NDA program RALEIGH, N.C., Dec. 2, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it engaged in a positive meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development program for Clonidine Topical Gel that will allow the program to proceed to Phase 3 clinical studies in the first quarter of 2014. (Logo:...

2013-11-04 08:27:24

Neuropathic Back Pain Continues to Account for the Largest Segment of the Neuropathic Pain Market, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the loss of U.S. and European market exclusivity of three sales-leading neuropathic pain (NP) agents--Eli Lilly/Shionogi's Cymbalta/Xeristar, Endo/Grunenthal's...

2013-10-03 08:29:13

INDIANAPOLIS, Oct. 3, 2013 /PRNewswire/ -- -- Company aims to overcome patent expirations through targeted growth initiatives, continued expense controls, and maturing Phase 3 pipeline -- Lilly expects to launch several new medicines beginning next year, returning the company to revenue growth and expanding margins after 2014 -- To date, positive Phase 3 results have led to a record seven regulatory submissions of four molecules in 2013 -- Lilly...

2013-06-30 23:00:54

Achieve Clinical is Conducting a Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of a New Drug for the Treatment of Patients with Fibromyalgia Birmingham, Alabama (PRWEB) June 30, 2013 ESTIMATED STUDY DURATION: 16-19 weeks. This includes 5 – 28 days in screening followed by 16 weeks of blinded study drug treatment. BACKGROUND & RATIONALE: Chronic pain affects an estimated 116 million American adults-- more than the...

2013-06-30 23:00:50

Avail Clinical is conducting an 11-week, Phase 2 Multicenter, Randomized, Double−Blind, Parallel−Group, Placebo−Controlled Study of a new drug in Subjects with Fibromyalgia (FM). DeLand, Florida (PRWEB) June 30, 2013 *To see if you qualify for this Fibromyalgia Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. STUDY POPULATION: Adults with fibromyalgia DURATION OF STUDY PARTICIPATION: Up to...